Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to $38.0 million.

  • Ani Pharmaceuticals' Free Cash Flow rose 395.33% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.7 million, marking a year-over-year increase of 102.84%. This contributed to the annual value of $47.8 million for FY2024, which is 56.60% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Free Cash Flow of $38.0 million as of Q3 2025, which was down 47.14% from $71.8 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Free Cash Flow's 5-year high stood at $71.8 million during Q2 2025, with a 5-year trough of -$20.9 million in Q1 2022.
  • In the last 3 years, Ani Pharmaceuticals' Free Cash Flow had a median value of $19.1 million in 2023 and averaged $27.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 11,578.36% in 2021, then slumped by 1,753.11% in 2022.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Free Cash Flow stood at -$12.5 million in 2021, then spiked by 39.89% to -$7.5 million in 2022, then surged by 663.29% to $42.5 million in 2023, then crashed by 68.29% to $13.5 million in 2024, then spiked by 395.33% to $38.0 million in 2025.
  • Its last three reported values are $38.0 million in Q3 2025, $71.8 million for Q2 2025, and $32.5 million during Q1 2025.